Equities Analysts Offer Predictions for ALUR Q3 Earnings

Allurion Technologies Inc. (NYSE:ALUR) – Equities researchers at Roth Capital boosted their Q3 2025 earnings estimates for shares of Allurion Technologies in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of ($0.13) for the quarter, up from their previous forecast of ($0.14). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($0.40) per share. Roth Capital also issued estimates for Allurion Technologies’ Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.54) EPS and FY2026 earnings at ($0.29) EPS.

A number of other analysts also recently issued reports on the company. TD Cowen began coverage on Allurion Technologies in a research report on Wednesday, October 2nd. They issued a “buy” rating and a $2.00 target price for the company. Roth Mkm began coverage on Allurion Technologies in a report on Friday, September 6th. They issued a “buy” rating and a $2.00 price objective for the company. Finally, Chardan Capital downgraded shares of Allurion Technologies from a “buy” rating to a “neutral” rating in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Allurion Technologies presently has an average rating of “Buy” and a consensus target price of $2.88.

Allurion Technologies Stock Up 11.3 %

Shares of ALUR stock opened at $0.38 on Monday. The firm has a market cap of $24.58 million, a P/E ratio of -0.80 and a beta of -0.37. The company has a 50 day moving average of $0.67 and a 200-day moving average of $1.02. Allurion Technologies has a 12-month low of $0.31 and a 12-month high of $4.24.

Institutional Trading of Allurion Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Accredited Investors Inc. grew its holdings in Allurion Technologies by 33.3% during the 2nd quarter. Accredited Investors Inc. now owns 50,000 shares of the company’s stock valued at $50,000 after buying an additional 12,500 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Allurion Technologies by 40.7% in the third quarter. Geode Capital Management LLC now owns 516,330 shares of the company’s stock valued at $317,000 after acquiring an additional 149,484 shares during the period. Finally, CVI Holdings LLC purchased a new position in Allurion Technologies during the second quarter valued at approximately $520,000. 21.39% of the stock is currently owned by institutional investors.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.